Developers targeting a liver disease called nonalcoholic steatohepatitis (NASH) are among the notable outperformers in the biopharma space this year, as Madrigal Pharmaceuticals (NASDAQ ...

Novo Nordisk and Eli Lilly are testing their respective blockbuster weight loss injections as treatments for the same kind of liver disease, called nonalcoholic steatohepatitis, or NASH.

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a ...

HepaStem is also advancing into the clinic in severe NASH. These studies mark the culmination of more than a decade of work to discover and refine liver specific cell-based therapies with ...